GenDx

10/03/2026

𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗼𝗻 𝗛𝗟𝗔 𝗶𝗻 𝗣𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆 🤰

Michael Eikmans, PhD, assistant professor at the Department of Immunology, Leiden University Medical Center, will discuss the unique features of HLA expression at the maternal–fetal interface and the relationship of maternal-fetal HLA incompatibility to outcomes. Insight into how variations in these features may contribute to pregnancy complications will also be reviewed.

📍 Online
📅 March 17, 2026
🕛 12:00 CET │ 19:00 CET
🔗Register: https://gendx.webinargeek.com/hla-in-pregnancy

𝗔𝗯𝗼𝘂𝘁 𝘄𝗲𝗯𝗶𝗻𝗮𝗿
A successful pregnancy poses an intriguing immunological paradox: although the fetus contains genetic material from both the mother and the father, the mother’s immune system normally accepts it rather than attacking it. This tolerance is achieved through carefully balanced immune processes that support a healthy pregnancy.

Human leukocyte antigens play a pivotal role in shaping immune tolerance, fetal development, and pregnancy outcomes. There is a fascinating immunological dialogue between mother and fetus. In pregnancy, semi-allogeneic fetal trophoblasts express a specific HLA profile mediating maternal leukocyte contact, crucial for placentation. Paradoxically, maternal immunomodulation requires fetal antigen recognition, involving certain HLA molecules.

10/03/2026

Since the early days of solid organ transplantation, closer HLA matching between donor and recipient has been linked to better graft survival, and this remains true even with the presence of efficient immunosuppression. Unfortunately, due to the high polymorphism of HLA and the scarcity of donors, most organ transplants are performed with at least one or more HLA mismatches. These mismatches can trigger the recipient’s immune system to form donor-specific antibodies (DSA), which damage the graft and may lead to rejection.

Considering that not every HLA mismatch will lead to DSA formation, and that antibodies are not formed against the whole HLA molecule but rather specific areas of the HLA molecule, it is relevant to look beyond the traditional HLA matching rules.

👉 Read the full blog post written by Cynthia Kramer, PhD, Scientist at GenDx: https://www.gendx.com/2026/02/not-all-hla-are-equal-is-hla-molecular-matching-the-future-of-solid-organ-transplantation-2/

26/02/2026

Read our new article👇

Thousands of new alleles are discovered every year, and thus a standardized nomenclature is needed

25/02/2026

𝗢𝘂𝗿 𝗻𝗲𝘄 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗼𝗻 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗽𝗮𝗴𝗲 𝗶𝘀 𝗟𝗶𝘃𝗲!

We have updated our website to better reflect our comprehensive Companion Diagnostics (CDx) solutions - from a biomarker idea to clinical implementation and registered IVD.

Explore how GenDx can support your pharmaceutical and biotech development journey.

🔗 Discover our CDx solutions 👉 https://www.gendx.com/companion-diagnostics/introduction/

24/02/2026

📩 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗻𝗲𝘄𝘀! 𝗡𝗲𝘅𝘁 𝘄𝗲𝗲𝗸, 𝘄𝗲 𝘄𝗶𝗹𝗹 𝗯𝗲 𝘀𝗵𝗮𝗿𝗶𝗻𝗴 𝗼𝘂𝗿 𝗳𝗶𝗿𝘀𝘁 𝗚𝗲𝗻𝗗𝘅 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿.

GenDx is a team of dedicated individuals who strongly believe in the importance of sharing knowledge and collaboration to advance the transplantation field. In this newsletter, we will share what we are learning and how it shapes our daily work.

Join us on this journey as we cultivate a community committed to improving the quality of life and survival of transplant patients.

Want to subscribe?
1️⃣ Click the link https://www.gendx.com/sign-up-for-our-newsletter/
2️⃣ Sign up for "General News."

11/02/2026

Register for our new webinar!

Our Scientist Cynthia Kramer, PhD, will provide an overview of the current HLA molecular matching approaches as well as ongoing discussion in the field.

📅 February 25
🕛 12:00 CET︱19:00 CET
📍Online

About webinar
Within the field of solid organ transplantation, HLA molecular matching is a hot topic. Over the past decade, multiple approaches have been introduced to predict HLA immunogenicity on the molecular level.

While, indeed, at the population level, an increasing number of molecular mismatches is strongly associated with the formation of de novo donor-specific antibody and worse graft survival after transplantation, at the patient level, it is not necessarily a numbers game. Not every HLA molecular mismatch is equally immunogenic, and immunological risk assessments require more than counting mismatches.

🔗Register here: https://www.gendx.com/gendx_education/not-all-hla-are-equal-is-hla-molecular-matching-the-future-of-solid-organ-transplantation/

09/02/2026

06/02/2026

Read the interview with our General Manager, Maarten Penning👇

https://www.gendx.com/2026/02/behind-the-scenes-of-a-professional-journey-interview-with-maarten-penning/

16/01/2026

We are pleased to invite you to our first webinar of the year - 𝗡𝗚𝗦𝗲𝗻𝗴𝗶𝗻𝗲® 𝗖𝗮𝘀𝗲 𝗦𝘁𝘂𝗱𝘆 𝗪𝗲𝗯𝗶𝗻𝗮𝗿 (𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗟𝗲𝘃𝗲𝗹) 💻

In the NGSengine® case study webinar series, we are dealing with interesting cases of NGS HLA data. This month, we will discuss an advanced case using Illumina-generated data. We aim for an interactive session while performing an in-depth analysis of the sample.

🗓️ 𝗗𝗮𝘁𝗲: January 28, 2026
⏲️ 𝗧𝗶𝗺𝗲: 12:00 CET︱19:00 CET
🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿: https://www.gendx.com/gendx_education/ngsengine-case-study-webinar-advanced-level/

14/01/2026

𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝘁𝗿𝗮𝗶𝗻𝗶𝗻𝗴 𝗰𝗼𝘂𝗿𝘀𝗲 𝗼𝗻 𝗛𝗟𝗔 𝘁𝘆𝗽𝗶𝗻𝗴 𝘂𝘀𝗶𝗻𝗴 𝗡𝗚𝗦!

Experience the full HLA workflow from lab techniques to in-depth data analysis.

This course includes:
☑️ Theoretical knowledge of HLA typing with NGS.
☑️ Hands-on training of multiplexed NGS HLA typing: One-Day-Workflow.
☑️ Training on data analysis with NGSengine®: from basics to case studies.

Participants are welcome to bring their own genomic DNA samples for typing (anonymized samples and data only).

This training course is ACHI accredited (3 CECs)

Secure your spot by registering via our website:
🔗https://www.gendx.com/registration-training-course-november-5-6-2026/

13/01/2026

Our team is currently working on the 𝗡𝗚𝗦𝗴𝗼‑𝗣𝗿𝗼𝗻𝘁𝗼𝗙𝗟𝗫 🧬

It is the perfect solution for when you need to prioritize depth of coverage and read length for a single sample, making it ideal for repeating analysis on a specific locus or when the highest quality data is needed.

You can already request a prototype by emailing us at sales@gendx.com 📩

Stay tuned for more updates and announcements.

07/01/2026

Meet 𝗢𝗡𝘁𝗿𝗮𝗰𝗸 𝗽𝗿𝗼𝘁𝗼𝘁𝘆𝗽𝗲 - an alternative to traditional Illumina-based chimerism assays.

Our prototype solution enables rapid and sensitive chimerism monitoring using Oxford Nanopore Technologies Sequencing platforms.

When to choose ONtrack❓
When you need urgent or time-sensitive results.

In our carousel, we describe each step of the easy workflow, including sequencing under 3 hours per sample.

Interested❓
📩 To place an order for our prototype, please reach out to our team at 𝘀𝗮𝗹𝗲𝘀@𝗴𝗲𝗻𝗱𝘅.𝗰𝗼𝗺